# Lumonus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumonus-pty

- Industry: Healthcare Specialists
- Headquarters: Sydney, Australia
- Website: www.lumonus.com
- Total disclosed funding: $19M
- Latest round: Series B (Mar 4, 2026)
- Investors on record: 4

## About

Based in Australia, Lumonus Pty Ltd specializes in providing intelligent software solutions for healthcare, enhancing care delivery in oncology and radiation therapy through innovative technology. Lumonus Pty Ltd is focused on developing advanced software solutions for healthcare. Headquartered in Sydney, Australia, the company recently raised AUD 3 million in series B funding from new investors Investible, and Brandon Capital Partners, with participation from returning investors Aviron and Oncology Ventures. The founder's details are not disclosed, and there are no mentions of subsidiaries or significant business pivots. Lumonus AI specializes in providing intelligent software solutions that integrate seamlessly with existing healthcare systems. Their core product, Lumonus AI, functions as a smart assistant designed to enhance care delivery, particularly in oncology and radiation therapy. By streamlining processes such as patient dosimetry, Lumonus AI enables healthcare teams to significantly reduce turnaround times from planning to execution, allowing for more efficient care and improved patient outcomes. The company serves a diverse clientele, including healthcare providers such as hospitals and oncology centers, with notable customers including UMass Chan Medical School and Tacoma Radiation Oncology Centers. Lumonus AI is primarily marketed in the United States and Australia, aiming to address the urgent need for high-quality, rapid patient care in complex medical cases.The revenue structure for Lumonus revolves around partnerships and business-to-business transactions, focusing on collaboration with healthcare institutions rather than direct consumer sales. Clients typically engage with Lumonus through subscription-based models or service agreements, which allow for ongoing access to their intelligent software solutions. For instance, healthcare providers may sign contracts that encompass comprehensive service bundles, ensuring they receive continuous software updates and support. The pricing plans for these services are structured to reflect the complexity and scale of the healthcare provider's needs, catering specifically to institutions requiring high-quality oncology solutions. Through these established relationships, Lumonus generates revenue by facilitating improved patient care and operational efficiency for its clients.Lumonus Pty Ltd is planning to innovate further with the development of new products aimed at enhancing their software solutions. The company is targeting market expansion into additional healthcare sectors in Australia and the United States by the end of the next fiscal year. In March 2026, Lumonus Pty Ltd raised AUD 3 million in series B funding from new investors Investible, and Brandon Capital Partners, with participation from returning investors Aviron and Oncology Ventures. The company will use the March 2026 funding to support its growth and expansion plans initiatives.

## Funding rounds

- Series B, Mar 4, 2026, $2.1M — Brandon Capital Partners, Investible, Aviron, Oncology Ventures
- Series B, Nov 6, 2025, $16M — Aviron, Oncology Ventures

## Investors

- Aviron — Series B
- Oncology Ventures (https://capitalatlas.ai/funds/oncology-ventures) — Series B
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series B
- Investible (https://capitalatlas.ai/funds/investible) — Series B